Equities

Gufic Biosciences Ltd

GUFICBIO:NSI

Gufic Biosciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)485.45
  • Today's Change11.95 / 2.52%
  • Shares traded260.41k
  • 1 Year change+85.36%
  • Beta1.2452
Data delayed at least 15 minutes, as of Nov 08 2024 10:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments135467265
Total Receivables, Net3,8282,3221,778
Total Inventory2,0051,8351,156
Prepaid expenses8.619.508.51
Other current assets, total298.581.01
Total current assets6,0054,6413,208
Property, plant & equipment, net4,6033,2851,554
Goodwill, net--00
Intangibles, net566.796.10
Long term investments187.840.08
Note receivable - long term142563346
Other long term assets898191
Total assets10,9258,6125,214
LIABILITIES
Accounts payable1,6631,3031,410
Accrued expenses4.253.052.34
Notes payable/short-term debt1,4201,11866
Current portion long-term debt/capital leases25415595
Other current liabilities, total380303291
Total current liabilities3,7202,8821,864
Total long term debt1,6552,069483
Total debt3,3293,342644
Deferred income tax2101.90
Minority interest------
Other liabilities, total204183174
Total liabilities5,6005,1342,523
SHAREHOLDERS EQUITY
Common stock1009797
Additional paid-in capital------
Retained earnings (accumulated deficit)5,2253,3812,594
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity5,3263,4782,691
Total liabilities & shareholders' equity10,9258,6125,214
Total common shares outstanding1009797
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.